 | Up a level |
2021
Tutt, Andrew N. J., Garber, Judy E., Kaufman, Bella, Viale, Giuseppe, Fumagalli, Debora, Rastogi, Priya, Gelber, Richard D., de Azambuja, Evandro 
ORCID: 0000-0001-9501-4509, Fielding, Anitra, Balmana, Judith, Domchek, Susan M., Gelmon, Karen A., Hollingsworth, Simon J., Korde, Larissa A., Linderholm, Barbro, Bandos, Hanna, Senkus, E., Suga, Jennifer M., Shao, Z., Pippas, Andrew W., Nowecki, Zbigniew, Huzarski, Tomasz, Ganz, Patricia A., Lucas, Peter C., Baker, Nigel, Loibl, Sibylle, McConnell, Robin, Piccart, Martine, Schmutzler, Rita, Steger, Guenther G., Costantino, Joseph P., Arahmani, Amal, Wolmark, Norman, McFadden, Eleanor, Karantza, Vassiliki, Lakhani, Sunil R., Yothers, Greg ORCID: 0000-0002-7965-7333, Campbell, Christine and Geyer, Charles E.
(2021).
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N. Engl. J. Med., 384 (25).
S. 2394 - 2406.
WALTHAM:
MASSACHUSETTS MEDICAL SOC.
ISSN 1533-4406
2020
Loibl, Sibylle, Jackisch, Christian, Seiler, Sabine, Rastogi, Priya, Huober, Lens, Denkert, Carsten, Schneeweiss, Andreas, Hanusch, Claus, Fasching, Peter A., Blohmer, Jens-Uwe, Untch, Michael, Rhiem, Kerstin, Solbach, Christine, Nekljudova, Valentina, Costantino, Joseph, Wolmark, Norman and Geyer, Charles (2020). A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze). Oncol. Res. Treat., 43. S. 24 - 26. BASEL: KARGER. ISSN 2296-5262